Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of care, according to Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.
At a Senate confirmation hearing for CMS administrator, Mehmet Oz, M.D., would not answer directly whether he would support budget cuts to the Medicaid program.
Lissy Hu, M.D., MBA, CEO of Ascend Learning, was one of Managed Healthcare Executive’s 2022 Emerging Leaders in Healthcare winners. The editors caught up with Hu as part of our new “Where Are They Now?” series spotlighting the career paths of past emerging leaders.
David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.
In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome and obesity — and treat it.
Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, according to new research published in Health Science Reports.
Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
At the 2025 American Academy of Dermatology (AAD) meeting, Steven Daveluy, M.D., associate professor and program director of dermatology at Wayne State University, discussed ongoing barriers to the early diagnosis of hidradenitis suppurativa and the latest advancements in treatment.
Reaching out to waitlisted patients and organizing the staff into high-volume teams for a week shrank the waitlist from more than 3,000 unseen patients to 300.
Here’s what you missed this week on Managed Healthcare Executive.
A reduction in emergency room visits is just one of the ways teledermatology has improved patient outcomes and reduced costs, according to Elizabeth K. Jones, M.D., an associate dermatology professor at Thomas Jefferson University Hospital in Philadelphia.
An overview of the definition of teledermatology and it’s three subtypes, according to Elizabeth K. Jones, M.D., FAAD, an associate dermatology professor at Thomas Jefferson University Hospital.
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the 2025 meeting of the Amercian Academy of Dermatology.
The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in another similar study, which had high favorable response rate in the placebo group.
Rebecca Vasquez, M.D., FAAD, said that while there is not enough data to support success stories yet, she has seen firsthand the ways addressing social drivers of health has impacted her patients.
Raising funding for research on social drivers of health may become an obstacle, given recent anti-DEI policies put into place by the federal government, according to Rebecca Vasquez, M.D., FAAD, a speaker at the 2025 American Academy of Dermatology meeting.
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial hypertension market.
Markary, a surgeon at Johns Hopkins, gave safe, vague and polished answers to senators' questions on mifepristone and the cancellation of an FDA vaccine committee meeting.
Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.
The experimental Healthy Opportunity Pilots (HOP) program reduced Medicaid spending by addressing the social needs of enrollees in 33 counties in North Carolina, according to evaluation results published in JAMA.
Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.
Environmental factors like diet and early antibiotic use have an impact on the gut microbiome and can contribute to inflammatory bowel disease (IBD), explained Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital.
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed.
Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history.
